Search
Predictive Oncology Inc
POAIAdd to Watchlist
5.950USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
75.12MMarket Cap
LossP/E TTM
More Details of Predictive Oncology Inc Company
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Predictive Oncology Inc Info
Ticker SymbolPOAI
Company namePredictive Oncology Inc
IPO dateDec 18, 2009
CEOVennare (Raymond F)
Number of employees23
Security typeOrdinary Share
Fiscal year-endDec 18
Address91 43Rd Street
CityPITTSBURGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code15201
Phone14124321500
Websitehttps://predictive-oncology.com/
Ticker SymbolPOAI
IPO dateDec 18, 2009
CEOVennare (Raymond F)
Company Executives of Predictive Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
19.68K
+0.01%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
15.86K
+59.21%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
13.07K
+43.32%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
+46.03%
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
19.68K
+0.01%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
15.86K
+59.21%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
13.07K
+43.32%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
+46.03%
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Predictive Oncology Inc?
The top five shareholders of Predictive Oncology Inc are: Mr. Raymond F. Vennare
How many institutions hold shares of Predictive Oncology Inc (POAI)?
As of 2026Q1, 40 institutions hold shares of Predictive Oncology Inc, with a combined market value of approximately 185.91K, accounting for 3.36% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 138692.00.